Elsevier

Journal of Hepatology

Volume 35, Issue 3, September 2001, Pages 421-430
Journal of Hepatology

Special Article
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference

https://doi.org/10.1016/S0168-8278(01)00130-1Get rights and content

Section snippets

Incidence and risk factors

The incidence in developing countries is two to three times higher than in developed countries. In Eastern Asia and Middle Africa the Age-Adjusted Incidence Rate (AAIR) ranges from 20 to 28 cases per 105 in men, while this is less than five per 105 in Northern Europe, Australia and America [1]. However, a steady increase has been observed in North America [2], but figures are still lower than in Southern Europe where the AAIR is around ten per 105 in men [1]. The calculation of the risk

Surveillance

Surveillance for HCC meets some but not all of the standard criteria for assessing the feasibility of instituting a cost-effective surveillance program for any disease [32]. HCC occurs sufficiently frequently in some at-risk populations and it induces significant morbidity and mortality. In the Western world, the population at risk readily accepts the need for screening, and physicians generally do believe that surveillance is necessary. However, the surveillance tests are imperfect, and recall

Surveillance tools

The available data on tumor growth suggest that the time from an undetectable lesion to 2 cm is about 4–12 months [35], [36], [37], [38]. Thus, with an aim of detecting tumors below 3 cm in diameter, the suggested interval for surveillance in patients with cirrhosis has been set at 6 months. Patients with a particularly high risk do not warrant a more intense surveillance schedule since a higher risk does not mean faster tumor growth. The surveillance tools are AFP concentration and

Recall procedures and diagnostic confirmation

There are no studies to define unequivocally the best recall policy, but based on the available clinical data the following scheme is advised (Fig. 1). The detection of a hypo- or hyperechoic nodule during follow-up US should raise the suspicion of HCC. However, pathological studies have shown that half of the nodules less than 1 cm in size do not correspond to HCC [41]. In addition, even if such a nodule corresponded to a true HCC, it is almost impossible to correctly diagnose it as such with

Assessment of disease extension

The indication to have accurate staging depends on the clinical need. In patients diagnosed at an advanced stage of disease with no therapeutic options, the results of diagnostic US provide enough information and no other techniques are necessary. In those individuals in whom a treatment decision has to be taken, tumor staging should be based on US and spiral CT. The use of lipiodol CT is not recommended because of its limited accuracy [50], [51]. CT should be done with latest generation

Prognostic assessment

The ideal system to estimate the prognosis of patients diagnosed with HCC should be as simple as possible to use, and yet include all important descriptive information associated with survival. Since the goal is to improve the prognosis by using a therapeutic intervention and because the possible interventions depend on the stage of the disease, both the stage and the various types of intervention should ideally be built into the prognostic system. The prognostic models in their present state

Definitions within clinical studies

Clinical investigations aiming to provide the most accurate and useful information should include a detailed and comprehensive report of the descriptive variables of all patients included. The variables to be recorded and described in outcome research should include those parameters that have been identified as significant predictors in previous investigations (Table 2). The data should be collected and reported in a standardized way to allow assessment of the comparability between groups of

Assessment of treatment response

The local response to treatment is relevant for the investigation of new therapeutic options. The evaluation of surgery is not subject to controversy, but the assessment of loco-regional treatment (i.e. percutaneous and transarterial procedures) requires a careful assessment of the treated HCC by imaging techniques. Spiral CT at least 4 weeks after the treatment is currently accepted as the standard imaging modality for this purpose [64]. Non-enhanced tumoral areas reflect tissue necrosis after

Definitions of response

Local response to treatment is usually defined following the World Health Organisation (WHO) criteria [65] as follows: complete response (CR): complete disappearance of all known disease and no new lesions determined by two observations not less than 4 weeks apart; partial response (PR): >50% reduction in total tumor load of all measurable lesions determined by two observations not less than 4 weeks apart; stable disease (ST): does not qualify for CR/PR or progressive disease; progressive

Treatment

There are no data to propose a universal treatment algorithm to be implemented worldwide. If diagnosed at an early stage, patients should be considered for any of the available options that may provide a high rate of CR. If these are not feasible, patients should be included in prospective investigations, preferably RCTs aiming to identify therapies that ultimately may lead to a survival improvement. Each group, center or country must establish the best treatment approach for patients with HCC

Prevention of HCC

Vaccination against HBV has decreased the incidence of HCC in areas with high prevalence of this viral agent [121]. Other strategies for primary prevention of HCC (i.e. Oltipraz [122]) are being tested but no solid data are yet available. Antiviral treatment for chronic hepatitis decreases the proportion of patients developing cirrhosis [123] and this should reduce the long-term incidence of this neoplasm [124]. When cirrhosis is already established, there is no evidence supporting a preventive

First page preview

First page preview
Click to open first page preview

References (128)

  • P Bedossa et al.

    An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

    Hepatology

    (1996)
  • F.P Sarasin et al.

    Cost-effectiveness of screening for detection of small hepatocellular carcinoma in Western patients with Child-Pugh class A cirrhosis

    Am J Med

    (1996)
  • M Ebara et al.

    Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients

    Gastroenterology

    (1986)
  • M Sherman

    Alphafetoprotein: an obituary

    J Hepatol

    (2001)
  • G.T Huang et al.

    Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma – a study based on 420 patients

    J Hepatol

    (1996)
  • F Mion et al.

    Adult cirrhotic liver explants: precancerous lesions and undetected small hepatocellular carcinomas

    Gastroenterology

    (1996)
  • T Bizollon et al.

    Diagnostic value and tolerance of Lipiodol-computed tomography for the detection of small hepatocellular carcinoma: correlation with pathologic examination of explanted livers

    J Hepatol

    (1998)
  • S Chevret et al.

    A new prognostic classification for predicting survival in patients with hepatocellular carcinoma

    J Hepatol

    (1999)
  • E Villa et al.

    Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival

    Hepatology

    (2000)
  • H Bismuth et al.

    Hepatobiliary surgery

    J Hepatol

    (2000)
  • S Arii et al.

    Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan

    Hepatology

    (2000)
  • P Johnson et al.

    Hepatocellular carcinoma and the art of prognostication

    J Hepatol

    (2000)
  • A Marcos

    Right lobe living donor liver transplantation: a review

    Liver Transpl

    (2000)
  • C Feray et al.

    European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group

    Gastroenterology

    (1999)
  • L Castellano et al.

    Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients

    J Hepatol

    (1997)
  • M Sato et al.

    Microwave coagulation therapy for hepatocellular carcinoma

    Gastroenterology

    (1996)
  • A Giorgio et al.

    Interstitial laser photocoagulation under ultrasound guidance of liver tumors: results in 104 treated patients

    Eur J Ultrasound

    (2000)
  • W.Y Lau et al.

    Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial

    Lancet

    (1999)
  • T Takayama et al.

    Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

    Lancet

    (2000)
  • K Ikeda et al.

    Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor. A prospective randomized study of hepatitis C virus-related liver cancer

    Hepatology

    (2000)
  • T Livraghi et al.

    No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis

    J Hepatol

    (1995)
  • F.X Bosch et al.

    Epidemiology of primary liver cancer

    Semin Liver Dis

    (1999)
  • H.B El Serag et al.

    Rising incidence of hepatocellular carcinoma in the United States

    N Engl J Med

    (1999)
  • T Poynard et al.

    Independent risk factors for hepatocellular carcinoma in French drinkers

    Hepatology

    (1991)
  • M Colombo et al.

    Hepatocellular carcinoma in Italian patients with cirrhosis

    N Engl J Med

    (1991)
  • H Tsukuma et al.

    Risk factors for hepatocellular carcinoma among patients with chronic liver disease

    N Engl J Med

    (1993)
  • L Bolondi et al.

    Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis

    Gut

    (2001)
  • F Villa et al.

    Risk factors for hepatocellular carcinoma in Italy. Male sex, hepatitis B virus, non-A non-B infection and alcohol

    Cancer

    (2000)
  • F.S Yeh et al.

    Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in Southern Guangxi, China

    Cancer Res

    (1989)
  • K Sakuma et al.

    Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study

    Hepatology

    (1988)
  • S Bruno et al.

    Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study

    Hepatology

    (1997)
  • K Ikeda et al.

    A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis

    Hepatology

    (1993)
  • F Degos et al.

    Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death

    Gut

    (2000)
  • C Niederau et al.

    Survival and causes of death in cirrhotic and in non-cirrhotic patients with primary hemochromatosis

    N Engl J Med

    (1985)
  • S Fargion et al.

    Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis

    Hepatology

    (1994)
  • M Mori et al.

    Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan

    Am J Epidemiol

    (2000)
  • Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study

    Contraception

    (1997)
  • H Oka et al.

    Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma

    Hepatology

    (1994)
  • Y Sato et al.

    Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein

    N Engl J Med

    (1993)
  • S.L Tsai et al.

    Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma

    Hepatology

    (1990)
  • Cited by (3871)

    View all citing articles on Scopus
    View full text